Article
Continuous selective intraarterial infusion of nimodipine for therapy of refractory cerebral vasospasm
Search Medline for
Authors
Published: | June 4, 2012 |
---|
Outline
Text
Objective: For endovascular treatment of vasospasm after aneurysmal subarachnoid hemorrhage (aSAH), an intraarterial treatment course with the calcium channel antagonist nimodipine infused for 30 min is proposed. As some patients still show ongoing vasospasm thereafter, we report our experience with an extended time period of selective intraarterial nimodipine administration.
Methods: In twenty patients with aSAH and refractory vasospasm, we left the catheter in place within the internal carotid artery after angiography. On the neurosurgical intensive care unit, a continuous infusion of intraarterial nimodipine was commenced, combined with intraarterial heparin anticoagulation. Therapy was controlled with extended neuromonitoring techniques.
Results: Four patients died from refractory vasospasm and a fifth suffered lethal sepsis. Fifteen patients survived in a good clinical condition, based on their Hunt&Hess grade. Seven of them recovered without an apparent neurological deficit. The efficacy of intraarterial nimodipine was best verified with regional cerebral blood flow monitoring. Transcranial doppler turned out to be unreliable with interexaminer variance and failure of detecting vasospasm or missing the improvement in some patients. Brain tissue oxygenation increased, but was not indicative of vasospasm. Computed tomography perfusion scanning reflected the treatment course adequately.
Conclusions: Selective continuous intraarterial nimodipine treatment for refractory cerebral vasospasm after aSAH seems feasible and may add to the endovascular therapeutic options. Appropriate monitoring technology is essential for further investigations of this novel technique.